ArticleGenes & diseases2026
H2AX phosphorylation driven by the SET-PP2A axis maintains glioma stem cell properties.
Article in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chemical Proteomic Profiling of the Histaminylation Proteome in Cancer Cells Unveils Uncharted Epigenetic Marks on Core Histones.Journal of the American Chemical Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma harbors a subpopulation of glioma stem cells (GSCs) that drive tumor relapse and invasion. Although GSC properties are known to be regulated by key transcription factors and chromatin remodeling, the mechanisms governing stemness-associated gene expression and the role of histone proteins in this process remain poorly understood. Here, we revealed that GSCs possessed an increased level of histone variant H2AX and phosphorylated H2AX at Ser 139 (γH2AX). CRISPR-Cas9-mediated deletion of H2AX demonstrated its critical role in maintaining GSC self-renewal, tumorigenicity, and the expression of multiple stemness-associated genes. Reintroduction of wild-type H2AX, but not the phosphorylation-deficient S139A mutant, restored GSC properties in H2AX-knockout cells, underscoring the importance of H2AX phosphorylation. We further identified that the elevated γH2AX levels in GSCs result from suppressed PP2A phosphatase activity, driven by increased expression of the SET oncoprotein. Pharmacological reactivation of PP2A effectively reduced γH2AX levels in GSCs. Collectively, our findings uncover a novel mechanism for GSC maintenance and highlight the SET-PP2A axis as a key regulator of γH2AX levels, offering a potential therapeutic target to disrupt GSC-driven tumor growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.